Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

New HHS initiatives put spotlight on long COVID

By Brian Buntz | July 31, 2023

HHS LogoThe U.S. Department of Health and Human Services (HHS) recently announced two major initiatives to shed light on long COVID, a condition affecting millions. First, the agency plans to establish the Office of Long COVID Research and Practice. HHS is also set to launch new long COVID-19 clinical trials through its RECOVER initiative. Jointly, the long COVID drug development efforts highlight the need for therapies and create openings for pharmaceutical companies to drive research and drug development related to the condition.

HHS has earmarked $1.15 billion for the RECOVER Initiative to explore novel therapies for the condition estimated to have affected between 7.7 and 23 million Americans. To date, the RECOVER Initiative has enrolled more than 24,000 participants in observational studies on long COVID. New clinical trials, beginning enrollment in summer 2023, will test experimental therapies across five focus areas to identify therapies that can alleviate symptoms and improve quality of life for long COVID patients.

Varied symptoms in long COVID

Long COVID manifests as persistent symptoms after acute COVID-19 infection. Roughly one out of five people who have contracted COVID-19 have had long-COVID symptoms, according to research from CDC. The agency defines the condition, which has symptoms varying from brain fog to shortness of breath, as lasting at least three months after infection.

Developing treatments remains a challenge given the significant variety in long COVID symptoms and patient presentations.

Long COVID drug development initiative from Virios Therapeutics

Pfizer’s Paxlovid, which pharmacists can prescribe, appears to help address long COVID symptoms in some patients, but treating the condition is not an official indication of the drug. A growing number of firms are exploring potential long COVID therapies, like Bateman Horne Center’s trial of Virios Therapeutics’ IMC-1. The research from the biotech Virios is among the most mature to date in the area. The company announced positive data showing improvement in multiple long-COVID symptoms after treatment with a combination of valacyclovir and celecoxib (Val/Cel) in an exploratory, open-label, proof of concept study. Valacyclovir is an antiviral drug while celecoxib is a nonsteroidal anti-inflammatory drug  (NSAID).

Female patients diagnosed with long COVID who received the so-called Val/Cel cocktail demonstrated clinically and statistically significant improvements in fatigue, pain and symptoms of autonomic dysfunction and general well-being related to long COVID when treated open-label with Val/Cel for 14 weeks. Virios plans to meet with the FDA in the second half of 2023 to discuss a potential investigational new drug application for a fixed dose combination of the two drugs, aimed at treating symptoms associated with PASC.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

institut pasteur dakar IPD African Union vaccine investment
African Union vaccine initiative receives $45M
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
This image shows the Moderna logo.
Moderna resizes its manufacturing footprint for a post-pandemic era
This is the logo of Pfizer.
Pfizer to close Durham and Morrisville, North Carolina facilities amid major restructuring effort
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE